- Home
- BMRN vs ACI Comparison
BMRN vs ACI Comparison
Compare BMRN & ACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- ACI
- Stock Information
- Founded
- BMRN 1996
- ACI 1860
- Country
- BMRN United States
- ACI United States
- Employees
- BMRN N/A
- ACI N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- ACI Food Chains
- Sector
- BMRN Health Care
- ACI Consumer Staples
- Exchange
- BMRN Nasdaq
- ACI Nasdaq
- Market Cap
- BMRN 9.9B
- ACI 9.6B
- IPO Year
- BMRN 1999
- ACI 2020
- Fundamental
- Price
- BMRN $54.90
- ACI $18.20
- Analyst Decision
- BMRN Buy
- ACI Buy
- Analyst Count
- BMRN 19
- ACI 14
- Target Price
- BMRN $90.26
- ACI $24.14
- AVG Volume (30 Days)
- BMRN 2.8M
- ACI 8.0M
- Earning Date
- BMRN 10-27-2025
- ACI 10-14-2025
- Dividend Yield
- BMRN N/A
- ACI 3.30%
- EPS Growth
- BMRN 59.53
- ACI N/A
- EPS
- BMRN 2.68
- ACI 1.69
- Revenue
- BMRN $3,094,001,000.00
- ACI $81,370,600,000.00
- Revenue This Year
- BMRN $13.32
- ACI $4.87
- Revenue Next Year
- BMRN $7.51
- ACI $0.54
- P/E Ratio
- BMRN $20.42
- ACI $10.75
- Revenue Growth
- BMRN 12.39
- ACI 2.08
- 52 Week Low
- BMRN $50.76
- ACI $16.70
- 52 Week High
- BMRN $73.51
- ACI $23.20
- Technical
- Relative Strength Index (RSI)
- BMRN 55.73
- ACI 51.75
- Support Level
- BMRN $50.76
- ACI $17.38
- Resistance Level
- BMRN $55.34
- ACI $17.92
- Average True Range (ATR)
- BMRN 1.76
- ACI 0.38
- MACD
- BMRN 0.33
- ACI 0.01
- Stochastic Oscillator
- BMRN 67.96
- ACI 62.84
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.